-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since its discovery as a century-old medicine, aspirin has made many contributions to human life and brought major changes to people's lives
.
In addition to the conventional anti-inflammatory and analgesic effects, it is also widely used for the prevention of cardiovascular diseases
Any drug has certain side effects, and aspirin is no exception, such as gastrointestinal bleeding, dementia, and cognitive impairment.
The former is mainly related to its stimulation of the gastrointestinal mucosa, while the mechanism of the latter is still unclear
.
To this end, some scholars have explored, aiming to conduct a pre-designated secondary analysis (with longer follow-up time) in the ASCEND study to evaluate the impact of low-dose aspirin on the risk of dementia and cognitive impairment, and conducted a report at the AHA conference Share
.
Research methods
Research methods
The study included 15,427 British diabetic patients with no history of cardiovascular disease and no record of dementia in the ASCEND trial between June 2005 and July 2011
.
They were randomly divided into two groups: aspirin group (10 mg/d) and placebo group.
15427
In addition, in addition to comparing the effects of aspirin on the outcome of generalized dementia, after adjusting for age, previous disease, and baseline risk factors, the researchers also assessed the association of aspirin with severe vascular events, major bleeding, and subsequent risk of dementia
.
Research result
Research result1.
During the treatment period (with an average follow-up of 7.
4 years) and after an average follow-up of 1.
7 years, a total of 1146 subjects developed dementia
.2.
The risk ratios of non-fatal severe vascular time (n=990) and massive hemorrhage (n=496) to the outcome of extensive dementia were 2.
39 (95%CI 1.
96-2.
92) and 1.
99 (1.
52-2.
60), respectively
.
(Analysis results will be announced separately after unblinding)
1.
During the treatment period (with an average follow-up of 7.
4 years) and after an average follow-up of 1.
7 years, a total of 1146 subjects developed dementia
.
2.
The risk ratios of non-fatal severe vascular time (n=990) and massive hemorrhage (n=496) to the outcome of extensive dementia were 2.
39 (95%CI 1.
96-2.
92) and 1.
99 (1.
52-2.
60), respectively
.
(Analysis results will be announced separately after unblinding)
In summary, the ASCEND study will provide additional evidence for the effect of aspirin on diabetic patients suffering from dementia, and we look forward to the publication of more trial results
Leave a message here
